Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
6 US States for Fly Fishing - 223 Most Amusing Messages At any point Sent Among Kids and Their Folks
- 3At least 18 Palestinians killed in latest clashes in Gaza
- 4Vote in favor of the handheld vacuum that you love for its strong attractions!
- 5Vietnam rethinks its flood strategy as climate change drives storms and devastation
- A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- Famous SUVs With Low Energy Utilization In 2024
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- Seoul says sorry after unapproved drone flights into North Korea
- Figure out how to Guarantee Your Dental Embeds Endure forever
